Zacks Research Comments on Apellis Pharmaceuticals, Inc.’s Q1 2025 Earnings (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Investment analysts at Zacks Research dropped their Q1 2025 earnings per share estimates for Apellis Pharmaceuticals in a research note issued to investors on Tuesday, April 23rd. Zacks Research analyst R. Department now anticipates that the company will earn ($0.01) per share for the quarter, down from their previous forecast of $0.06. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.33) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q3 2025 earnings at $0.39 EPS and FY2025 earnings at $1.05 EPS.

Several other analysts have also issued reports on APLS. Raymond James upped their target price on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a research note on Thursday, January 11th. Needham & Company LLC reissued a “buy” rating and set a $85.00 price objective on shares of Apellis Pharmaceuticals in a research note on Tuesday, April 9th. HC Wainwright reissued a “buy” rating and set a $92.00 price objective on shares of Apellis Pharmaceuticals in a research note on Monday, April 15th. Mizuho reissued a “neutral” rating and set a $60.00 price objective on shares of Apellis Pharmaceuticals in a research note on Wednesday, March 27th. Finally, The Goldman Sachs Group increased their price objective on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, January 9th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $77.93.

Apellis Pharmaceuticals Stock Up 2.5 %

Shares of APLS opened at $49.93 on Thursday. The firm has a market cap of $6.02 billion, a P/E ratio of -11.15 and a beta of 0.88. The stock has a 50 day simple moving average of $58.61 and a two-hundred day simple moving average of $57.37. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50. Apellis Pharmaceuticals has a 1 year low of $19.83 and a 1 year high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.73). The business had revenue of $146.38 million during the quarter, compared to analyst estimates of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. Apellis Pharmaceuticals’s revenue for the quarter was up 545.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.50) earnings per share.

Insiders Place Their Bets

In other Apellis Pharmaceuticals news, insider Nur Nicholson sold 835 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $64.14, for a total value of $53,556.90. Following the completion of the transaction, the insider now owns 67,507 shares in the company, valued at $4,329,898.98. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Apellis Pharmaceuticals news, insider Nur Nicholson sold 835 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $64.14, for a total value of $53,556.90. Following the completion of the transaction, the insider now owns 67,507 shares in the company, valued at $4,329,898.98. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Pascal Deschatelets sold 69,107 shares of the stock in a transaction on Monday, April 8th. The stock was sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at approximately $60,452,799.11. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 381,011 shares of company stock worth $23,463,657. 7.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in APLS. First Horizon Advisors Inc. raised its holdings in Apellis Pharmaceuticals by 69.0% in the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock worth $25,000 after purchasing an additional 265 shares in the last quarter. Future Financial Wealth Managment LLC bought a new position in shares of Apellis Pharmaceuticals during the first quarter valued at $29,000. Covestor Ltd increased its holdings in shares of Apellis Pharmaceuticals by 564.2% during the third quarter. Covestor Ltd now owns 797 shares of the company’s stock valued at $30,000 after acquiring an additional 677 shares in the last quarter. Stephens Consulting LLC bought a new position in shares of Apellis Pharmaceuticals during the third quarter valued at $38,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Apellis Pharmaceuticals by 29.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,028 shares of the company’s stock valued at $115,000 after acquiring an additional 687 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).